Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
uniQure NVLTS:0EE0 -1.98%37 3-Year EBITDA Growth Rate is 4.30% as of Jun. 2026. GuruFocus rates LTS:0EE0 with a GF Score™ of 37/100 and a GF Value™ of $7.96 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,124 Biotechnology companies, uniQure NV ranks worse than 64.15% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 4.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of uniQure NV was 17.10% per year. The lowest was -47.10% per year. And the median was -3.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
uniQure NV 3-Year EBITDA Growth Rate Related Terms
LTS:0EE0 vs TARS, IMNM, IOVA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, uniQure NV's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where uniQure NV's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 4.30% mean?
uniQure NV (LTS:0EE0) has a 3-Year EBITDA Growth Rate of 4.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for uniQure NV and its competitors. According to the industry distribution chart, uniQure NV ranks #721 out of 1124 companies in the Biotechnology industry, placing it in the top 64.1%.
Is uniQure NV's 3-Year EBITDA Growth Rate too high?
uniQure NV's current 3-Year EBITDA Growth Rate is 4.30%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.65. uniQure NV's value of 4.30% is 70.6% below this industry median. Based on the distribution chart, uniQure NV ranks #721 out of 1124 companies in the Biotechnology industry, which is below the industry midpoint. Overall, uniQure NV has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's 3-Year EBITDA Growth Rate compare to TARS and IMNM?
According to the Biotechnology industry distribution chart, uniQure NV ranks #721 out of 1124 companies for 3-Year EBITDA Growth Rate. This places uniQure NV in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.65. uniQure NV's value of 4.30% is 70.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,124 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. uniQure NV's current 3-Year EBITDA Growth Rate of 4.30% is 70.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for uniQure NV and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. uniQure NV's current 3-Year EBITDA Growth Rate is 4.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (LTS:0EE0) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.96, compared to a current price of $42.65 — trading 435.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 4.30% and 70.6% below the Biotechnology industry median of 14.65. uniQure NV's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For uniQure NV (LTS:0EE0), the current 3-Year EBITDA Growth Rate is 4.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (LTS:0EE0) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of $42.65 is trading 435.8% above its estimated GF Value™ of $7.96.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for LTS:0EE0:
3-Year EBITDA Growth Rate: 4.30%
GF Value™: $7.96 vs. price of $42.65 (435.8% above fair value)
Industry Position: 70.6% below the Biotechnology median (#721 of 1124)
No single metric tells the full story. See the LTS:0EE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
37GF Score
Get the complete analysis for LTS:0EE0
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0EE0 has been successfully added to your 
